Innocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical Officer
“Lesley’s background in drug development and regulatory experience at both emerging and established biopharmaceutical companies is an excellent fit for us as we progress toward commercialization. Her experience to further develop our programs and articulate them to the
Dr. Russell has extensive experience managing the development of pharmaceuticals and biologics across a wide range of therapeutic areas, dosage forms and formulations on a global scale. Most recently, she was chief operating officer and chief medical officer at
“Innocoll’s collagen platform has the potential to generate product candidates into the future beyond the two late-stage candidates that will complete Phase 3 studies this year and a third that will soon enter Phase 3 development,” said Dr. Russell. “I am looking forward to working with the team as the company advances through planned commercialization of its lead candidates and generates new candidates to sustain growth for the long-term.”
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native collagen products—from extraction/purification of type-1 collagen through final delivery form—are manufactured at our certified, integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com.
CollaRx®, Collatamp®, COLLAGUARD®, Collieva®, CollaCare®, Collexa®, COGENZIA® LidoColl®, LiquiColl®, and XARACOLL® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.
Any statements in this press release about our future expectations, plans and prospects, including statements about the development of our product candidates and the timing, conduct, enrollment and outcome of our clinical studies, the availability of data from those studies, our ability to sell any approved products, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied. Such risks and uncertainties include, among others, those related to the timing and costs involved in developing and commercializing our products and product candidates, the timing for clinical trials and results, delays in potential approvals by
Pepe CarmonaChief Financial Officer (215) 983-3362 firstname.lastname@example.org Jeannie Sorenson, M.D.Vice President, Investor Relations (314) 458-7355 email@example.com